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SUMMARY – Th e aim of this study was to evaluate the implementation of the 9th edition of the 
American College of Chest Physicians (ACCP9) guidelines for prevention of venous thromboembo-
lism in nonsurgical patients in clinical practice in one university and one general Croatian hospital. A 
retrospective study was conducted at Zadar General Hospital from Zadar and Dubrava University 
Hospital from Zagreb. Medical charts of all patients admitted to Medical Departments in two peri-
ods, before and after implementation of the ACCP9 guidelines, were analyzed. Th e ACCP9 guide-
lines were made available to all physicians through the hospital electronic information system imme-
diately after the publication. Th e Hospital Drug Committees promoted implementation of the guide-
lines during their periodical clinical visits. Overall, 850 patients were included in the study in two 
periods. Th ere was no statistically signifi cant diff erence in the number of high-risk patients receiving 
thromboprophylaxis after the guidelines implementation in either hospital. In both periods, a signifi -
cantly higher number of high-risk patients received thromboprophylaxis in Dubrava University Hos-
pital in comparison with Zadar General Hospital (31.7% vs. 3.8% and 40.3% vs. 7.3%, respectively; 
p<0.001). Th is study revealed insuffi  cient implementation of evidence-based thromboprophylaxis 
guidelines in clinical practice in two Croatian hospitals.
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Introduction
Venous thromboembolism (VTE) comprises deep 
vein thrombosis (DVT) and pulmonary embolism 
(PE). It is an important cause of morbidity and mor-
tality in hospitalized patients, and treatment of VTE 
and related long-term morbidities is associated with 
considerable costs to the health care system1,2.
Pulmonary embolism, which is the most serious 
complication of VTE, is the third most common life-
threatening cardiovascular disease, after myocardial 
infarction and stroke3. It accounts for 5%-10% of 
deaths in hospitalized patients, making PE the most 
common preventable cause of in-hospital deaths4. Th e 
exact incidence of VTE is diffi  cult to estimate because 
it is often asymptomatic and unrecognized. Th e inci-
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dence varies, ranging from 76 to 117 cases/100,000 
patients5-7 in the US, and from 160 to 180 cas-
es/100,000 patients in Europe8,9. Although VTE is 
often regarded as a surgical complication, about three-
quarters of hospitalized patients who suff er a fatal PE 
are, in fact, medical patients10.
Th e eff ectiveness and safety of thromboprophylaxis 
has been supported by the evidence from several ran-
domized clinical trials conducted in medical pa-
tients11-13. However, underuse of routine thrombopro-
phylaxis has been reported. Th ree large-scale preven-
tion studies ENDORSE, IMPROVE and DVT-
FREE showed that appropriate thromboprophylaxis 
rates in at-risk medical patients varied from 39.5% to 
60.0% and that thromboprophylaxis rates in surgical 
patients were higher than in medical patients14-16.
Th romboprophylaxis in clinical practice can be im-
proved by the implementation of guidelines for the 
risk assessment and prevention of VTE. However, 
there are always physicians who do not apply the 
guidelines consistently17.
Th e American College of Chest Physicians (ACCP) 
guidelines for prevention of VTE in nonsurgical pa-
tients include recommendations for the risk assessment 
and prevention of VTE in medical patients18. Th e 9th 
edition (ACCP9) of the guidelines was published in 
February 2012 and their implementation in clinical 
practice has not yet been evaluated.
Th e aim of the study was to evaluate the imple-
mentation of ACCP9 guidelines in clinical practice in 
two Croatian hospitals, one university and one general.
Patients and Methods
Study design and setting
A retrospective study was conducted at two Croa-
tian hospitals, Zadar General Hospital from Zadar 
and Dubrava University Hospital from Zagreb. Th e 
former is a non-teaching hospital with 500 beds; the 
latter is a university-based teaching hospital with 1000 
beds. Th ese hospitals were chosen because of the pos-
sible diff erence in clinical practice between university 
and general hospitals.
Th e study was approved by the research Ethics 
Committees of the Zadar General Hospital and Du-
brava University Hospital.
Guideline distribution
Th e ACCP9 guidelines for prevention of VTE in 
nonsurgical patients were published in February 2012. 
Immediately after the publication, the guidelines be-
came available to all physicians in Zadar General Hos-
pital and Dubrava University Hospital via hospital 
electronic information system.
Each hospital has a Hospital Drug Committee, 
which evaluates and promotes the rational use of 
drugs. Th e Committee members periodically conduct 
clinical visits, during which they discuss therapeutic is-
sues with hospital physicians. After distribution of the 
ACCP9 guidelines, the Hospital Drug Committee 
evaluated the use of thromboprophylaxis and promot-
ed the implementation of the guidelines during their 
periodical clinical visits, which took place approxi-
mately every three months. Medical records of hospi-
talized patients were evaluated during the visit and 
guideline implementation issues were discussed with 
physicians.
Data collection
We evaluated medical charts of all patients admit-
ted to the Medical Departments of the Zadar General 
Hospital and Dubrava University Hospital between 
January 1 and January 31, 2012, i.e. in the period be-
fore the implementation of the guidelines, and be-
tween January 1 and January 31, 2013, i.e. in the period 
after the implementation of the guidelines. For each 
patient included in the study, we collected data on the 
assessment of the VTE risk (presence of an active can-
cer, previous VTE, reduced mobility, known thrombo-
philic condition, recent (≤1 month) trauma and/or 
surgery, older age (≥70 years), heart and/or respiratory 
failure, acute myocardial infarction or ischemic stroke, 
acute infection and/or rheumatologic disorder, obesity 
(BMI ≥30), and ongoing hormonal treatment)18. Data 
were entered into an electronic database developed by 
the researchers for use in the study.
We excluded from the study medical charts of the 
patients that had an indication for anticoagulation 
therapy (e.g., DVT, atrial fi brillation) and patients 
that had an excessive risk of bleeding as defi ned by 
the ACCP9 guidelines (active gastroduodenal ulcer, 
bleeding in 3 months before admission, platelet count 
<50x109/L, and multiple risk factors for bleeding)18.
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Risk assessment model
In order to assess the VTE risk and to determine 
adequacy of thromboprophylaxis, the ACCP9 guide-
lines for prevention of VTE in nonsurgical patients 
were used18. Th e guidelines have adopted the Padua 
Prediction Score risk assessment model, which is based 
on the principle of assigning points to each of the 11 
common VTE risk factors19. Using this model, we cat-
egorized study patients in two groups: low-risk (score 
<4) and high-risk (score ≥4) patients.
We reviewed medical charts to identify the use of 
thromboprophylaxis during hospitalization and to de-
termine whether the study patients were receiving 
 appropriate thromboprophylaxis. For high-risk medi-
cal patients, the ACCP9 guidelines recommend the 
VTE prophylaxis with low molecular weight heparin, 
low dose unfractionated heparin or fondaparinux. For 
low-risk medical patients, no thromboprophylaxis is 
recommended18.
Statistical analysis
We determined the proportion of high-risk and 
low-risk patients and the proportion of patients re-
ceiving adequate prophylaxis. Th e χ2-test was used to 
test diff erences between categorical variables. Th e val-
ues of p<0.05 were considered statistically signifi cant. 
All tabulations and statistical analyses were done using 
Statistica version 5.5 for Windows (StatSoft Inc. Tul-
sa, OK, USA).
Results
Medical charts of 204 patients admitted in January 
2012 and of 216 patients admitted in January 2013 to 
the Medical Department of Dubrava University Hos-
pital were included in the study (Table 1). Th ere was 
no statistically signifi cant diff erence in the number of 
high-risk patients receiving thromboprophylaxis be-
tween the two study periods. However, a signifi cantly 
higher number of low-risk patients received prophy-
laxis in January 2013.
We included in the study medical charts of 224 pa-
tients admitted in January 2012 and of 206 patients 
admitted in January 2013 to the Medical Department 
of Zadar General Hospital (Table 2). Th ere was no 
statistically signifi cant diff erence in the number of pa-
Table 1. Dubrava University Hospital – thromboprophylaxis in medical patients in January 2012 
and January 2013
January 2012 January 2013
p value*
Overall number of patients 204 216
High-risk patients, n (%)
received prophylaxis, n (%)








Low-risk patients, n (%)
received prophylaxis, n (%)









Table 2. Zadar General Hospital – thromboprophylaxis in medical patients in January 2012 and 
January 2013
January 2012 January 2013
p value*
Overall number of patients 224 206
High-risk patients, n (%)
received prophylaxis, n (%)








Low-risk patients, n (%)
received prophylaxis, n (%)
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tients receiving thromboprophylaxis between the Jan-
uary 2012 and January 2013 study periods.
In both periods, high-risk medical patients re-
ceived thromboprophylaxis signifi cantly more often in 
Dubrava University Hospital than in Zadar General 
Hospital (Table 3).
Discussion
To the authors’ knowledge, this is the fi rst study 
evaluating the implementation of the ACCP9 guide-
lines in clinical practice. Th e results indicated that the 
implementation of the guidelines through the hospital 
information system and with support of the Hospital 
Drug Committee did not improve the thrombopro-
phylaxis rate in high-risk medical patients in two Cro-
atian hospitals. Previous studies have also reported in-
suffi  cient implementation of thromboprophylaxis 
guidelines. In the study by Amin et al., only 9.8% of 
medical patients received thromboprophylaxis in ac-
cordance with the guidelines20. Obviously, the stricter 
and immediate education of physicians is needed to 
overcome the implementation gap21. Educational pro-
grams have been eff ective in increasing the rate of 
thromboprophylaxis22.
Surprisingly enough, in Dubrava University Hos-
pital, signifi cantly more low-risk medical patients re-
ceived thromboprophylaxis after the implementation 
of the guidelines. Th is could be the result of physicians’ 
misunderstanding of the guidelines and having diffi  -
culties with risk assessment in medical patients. Since 
the assessment of VTE risk is simpler in surgical pa-
tients, it could result in a higher rate of thrombopro-
phylaxis compared with medical patients14-16.
Alarmingly high proportions of high-risk medical 
patients did not receive thromboprophylaxis. Th ese 
proportions were higher than those reported in previ-
ous studies14-16. Th is could be attributed to diff erences 
in clinical practice standards and physician education 
in diff erent countries.
In both study periods, the number of high-risk 
medical patients receiving thromboprophylaxis was 
signifi cantly higher in Dubrava University Hospital 
than in Zadar General Hospital. Th is diff erence was 
probably the result of greater fi nancial resources and 
better educated physicians in university hospitals. Our 
results are consistent with the studies conducted in 
Canada and the USA by Kahn et al.23 and Amin et 
al.24, who also report greater use of thromboprophy-
laxis in university hospitals. Other studies did not de-
tect such diff erence14-16.
Strengths and limitations
Th e strength of our study was that we evaluated the 
implementation of the guidelines in one university 
hospital and one general hospital. Th is allowed us to 
limit the potential bias due to diff erences in clinical 
practice, physicians’ knowledge, and so on.
Th e fi rst limitation of our study was the limited 
quality of collected data due to its retrospective design. 
For instance, it was not possible to evaluate if the dura-
tion of thromboprophylaxis was in accordance with 
the guidelines, since changes in patient mobility could 
not be assessed from their medical charts. Another 
limitation was that we could not control the use of al-
ternative guidelines or standards for thromboprophy-
laxis, which could have infl uenced the study results. 
Also, our study included only two hospitals and the 
rate of thromboprophylaxis is likely to vary across the 
hospitals because of the diff erence in local standards 
and knowledge. Th erefore, the results of our study 
should be interpreted having these limitations in mind.
Table 3. Diff erence in use of thromboprophylaxis in high-risk medical patients 
between Dubrava University Hospital and Zadar General Hospital
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Th is study demonstrated insuffi  cient implementa-
tion of evidence-based thromboprophylaxis guidelines 
in clinical practice and signifi cant diff erence between 
university and general hospitals. Up to more than half 
of hospitalized medical patients were at a high risk of 
VTE, but only up to one-third of them received 
thromboprophylaxis. Th e proportion of patients re-
ceiving thromboprophylaxis did not signifi cantly in-
crease after the implementation of the ACCP9 guide-
lines. Underuse of VTE prophylaxis will certainly in-
crease in-hospital mortality. To improve patient safety, 
more eff ort is needed to increase the extent of imple-
mentation of the current thromboprophylaxis guide-
lines25.
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Sažetak
PRIMJENA SMJERNICA ZA PROFILAKSU VENSKE TROMBOEMBOLIJE U KLINIČKOJ PRAKSI: 
RETROSPEKTIVNO ISTRAŽIVANJE U DVJEMA HRVATSKIM BOLNICAMA
S. Marušić, A. Knežević, V. Bačić Vrca, I. Marinović, J. Bačić, P. R. Obreli Neto, D. Amidžić Klarić i D. Diklić
Cilj ovoga retrospektivnog istraživanja bio je procijeniti primjenu 9. izdanja smjernica American College of Chest Physicians 
(ACCP9) za prevenciju venske tromboembolije u nekirurških bolesnika u kliničkoj i općoj bolnici u Republici Hrvatskoj. 
Istraživanje je provedeno u Općoj bolnici Zadar i Kliničkoj bolnici Dubrava u Zagrebu. Analizirana je medicinska dokumen-
tacija svih bolesnika hospitaliziranih na internističke odjele u razdoblju prije i nakon implementacije smjernica ACCP9. 
Smjernice su bile dostupne svim liječnicima putem bolničkih informatičkih sustava. Bolnička povjerenstva za lijekove su 
 tijekom periodičkih kliničkih vizita promovirala primjenu smjernica u kliničkoj praksi. U razdoblju prije i nakon implemen-
tacije smjernica u istraživanje je uključeno ukupno 850 bolesnika. Niti u jednoj bolnici nije bilo statistički značajne razlike u 
broju visoko rizičnih bolesnika koji su dobili tromboprofi laksu nakon implementacije smjernica. U oba razdoblja je broj 
 visoko rizičnih bolesnika koji su dobili tromboprofi laksu bio značajno veći u Kliničkoj bolnici Dubrava u odnosu na Opću 
bolnicu Zadar (31,7% prema 3,8% i 40,3% prema 7,3%; p<0,001). Rezultati istraživanja ukazuju na nedostatnu implemen-
taciju smjernica za tromboprofi laksu u dvjema hrvatskim bolnicama.
Ključne riječi: Venska tromboembolija; Kliničke smjernice kao tema; Farmaceutska i terapijska komisija; Retrospektivne studije; 
Hrvatska
